NDAORALTABLET
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral H2-receptor antagonist tablet containing ranitidine hydrochloride, a small-molecule histamine blocker used to reduce gastric acid production. It treats peptic ulcer disease, gastroesophageal reflux disease (GERD), and other acid-related conditions by inhibiting histamine-stimulated acid secretion in the stomach. The drug has been a foundational therapy in acid suppression for decades.
LOE Approaching
This product is approaching loss of exclusivity, signaling potential downsizing of the brand team and shift toward lifecycle management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Working on ZANTAC 150 in 2024 positions you in a late-lifecycle, cost-management function rather than a growth-focused role, with emphasis on generic transition strategy and market-share defense. Opportunities are concentrated in commercial operations, pricing strategy, and business development rather than innovative drug development.
Brand Manager
Worked on ZANTAC 150 at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.